kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
49
JPY
-2
(-3.92%)
Dec 12, 3:30 pm JST
0.31
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
49.1
Dec 12, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.62
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
50 JPY 0.32 USD
Previous Close Dec 11
51 JPY 0.32 USD
High Dec 12, 9:50 am
52 JPY 0.33 USD
Low Dec 12, 1:54 pm
49 JPY 0.31 USD
Volume
2,170,100
Trading Value
0.11B JPY 0.70M USD
VWAP
50.18 JPY 0.32 USD
Minimum Trading Value
4,900 JPY 31 USD
Market Cap
5.46B JPY 0.04B USD
Number of Trades
162
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
553
1-Year High Aug 15, 2025
10,957
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 1,405,000 11,860,200 8.44
Nov 28, 2025 1,405,000 12,452,400 8.86
Nov 21, 2025 1,405,000 13,142,500 9.35
Nov 14, 2025 1,425,100 13,686,800 9.60
Nov 7, 2025 1,421,100 13,865,000 9.76
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.